Skip to main content

Market Overview

Soligenix Shares Rally On Positive Preclinical Data For COVID-19 Vaccine Candidate


Soligenix Inc (NASDAQ: SNGX) rises sharply in premarket trading after the publication of positive results from pre-clinical immunogenicity studies for the COVID-19 vaccine candidate, dubbed as CiVax.

  • The data demonstrated rapid-onset, neutralizing antibody and cell-mediated immunity using full-length Spike protein antigens.
  • This work will continue under a $1.5M Small Business Innovation Research (SBIR) grant awarded to Soligenix in December last year.
  • CiVax is Soligenix's heat-stable subunit vaccine candidate for the prevention of COVID-19 infection.
  • The following steps will include evaluating immunogenicity in a non-human primate model and assessing antibody coverage with key variants of the virus.
  • Price Action: SNGX shares gained 34.8% at $2.18 in premarket trading on the last check Thursday.

Related Articles (SNGX)

View Comments and Join the Discussion!

Posted-In: COVID-19 VaccineBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at